GlassScriptPhysician profile
Alia Rivas
NPI 1386420552
$1,390.01
in general payments reported to CMS, 2019-2025
20 companies · $593 in 2025
The $593 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $797 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $292.34 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $257.63 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $110.86 | 2024-2025 | |
| Organon LLC | $107.01 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $92.48 | 2024-2025 | Rexulti |
| Dexcom, INC. | $89.75 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.05 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $64.82 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $43.76 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $42.60 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $37.43 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $33.48 | 2024-2025 | Repatha, Otezla, Otezla |
| Viiv Healthcare Company | $26.64 | 2025 | Cabenuva |
| Mylan Specialty L.P. | $22.64 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.90 | 2025 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $19.24 | 2025 | Dyanavel Xr |
| Pfizer INC. | $17.70 | 2024 | |
| Corcept Therapeutics | $16.02 | 2024 | Korlym |
| Abbvie INC. | $15.32 | 2024 | |
| Antares Pharma, INC. | $14.34 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alia Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.